These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 33109495)
1. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495 [TBL] [Abstract][Full Text] [Related]
2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ; BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519 [TBL] [Abstract][Full Text] [Related]
3. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma. Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753 [TBL] [Abstract][Full Text] [Related]
4. The Impact of Histological Variants on Oncological Outcomes After Surgical Resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-institutional Study. Fleury R; Bertail T; Bensalah K; Bernhard JC; Audenet F; Waeckel T; Parier B; Champy C; Olivier J; Doumerc N; Tricard T; Branger N; Bruyere F; Neuville P; Surlemont L; Alexandre Long J; Fontenil A; Vallee M; Roupret M; Boissier R; Jacques Patard J; Durand M; Ouzaid I; Rouget B; Durand X; Joncour C; Belas O; Denise Gomez F; Bigot P; Khene ZE; Eur Urol Open Sci; 2024 Apr; 62():123-130. PubMed ID: 38496822 [TBL] [Abstract][Full Text] [Related]
5. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland. Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053 [TBL] [Abstract][Full Text] [Related]
6. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy? Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson E; Lam TBL; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Bensalah K; Dabestani S; Bex A BJU Int; 2021 Sep; 128(3):386-394. PubMed ID: 33794055 [TBL] [Abstract][Full Text] [Related]
7. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. Dabestani S; Beisland C; Stewart GD; Bensalah K; Gudmundsson E; Lam TB; Gietzmann W; Zakikhani P; Marconi L; Fernandéz-Pello S; Monagas S; Williams SP; Torbrand C; Powles T; Van Werkhoven E; Meijer R; Volpe A; Staehler M; Ljungberg B; Bex A Eur Urol Focus; 2019 Sep; 5(5):857-866. PubMed ID: 29525381 [TBL] [Abstract][Full Text] [Related]
8. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350 [TBL] [Abstract][Full Text] [Related]
9. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma. Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958 [TBL] [Abstract][Full Text] [Related]
11. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798 [TBL] [Abstract][Full Text] [Related]
12. Association of Elevated C-Reactive Protein with Worsened Outcomes in Different Histologies of Renal Cortical Tumors: Analysis of the INMARC Registry. Saitta C; Afari JA; Patil D; Tanaka H; Yuen KL; Wang L; Cortes J; Liu F; Mahmood M; Matian J; Mansour M; Puri D; Cerrato C; Nguyen MV; Hakimi K; Kobayashi M; Fukuda S; Meagher MF; Fujii Y; Master V; Derweesh IH Clin Genitourin Cancer; 2024 Jun; 22(3):102098. PubMed ID: 38733897 [TBL] [Abstract][Full Text] [Related]
13. Stage IA papillary and chromophobe renal cell carcinoma: effectiveness of cryoablation and partial nephrectomy. Uhlig A; Uhlig J; Shuch B; Kim HS Insights Imaging; 2024 Jul; 15(1):171. PubMed ID: 38971873 [TBL] [Abstract][Full Text] [Related]
14. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types. Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353 [TBL] [Abstract][Full Text] [Related]
17. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037 [TBL] [Abstract][Full Text] [Related]
18. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V; Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752 [TBL] [Abstract][Full Text] [Related]
20. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK Front Immunol; 2023; 14():1182581. PubMed ID: 37638025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]